Skip to main content
. 2017 Dec 7;32(2):174–190. doi: 10.1177/0269881117743484

Figure 4.

Figure 4.

Expression of synaptic markers in the hippocampus of Tc1 mice injected with amyloid-β [25-35] (Aβ25-35) peptide. Wildtype (WT) or Tc1 mice were administered intracerebroventricular (i.c.v.) injections with scrambled peptide (Sc.Aβ) or Aβ25-35 peptide (9 nmol) and sacrificed 10 days after injection. The levels of synaptic markers were assessed in the half-hippocampus by enzyme-linked immunosorbent assay and reported to the level of proteins (mg): Arc (a), Egr1 (b), PSD95 (c) and synaptophysin (d). The number of animals per group is indicated below the columns. Two-way analysis of variance (ANOVA): F(1,33)=5.11, p<0.05 for the genotype, F(1,33)=4.69, p<0.05 for the treatment, F(1,33)=2.54, p>0.05 for the interaction in (a); F(1,36)=0.173, p>0.05 for the genotype, F(1,36)=0.261, p>0.05 for the treatment, F(1,36)=0.232, p>0.05 for the interaction in (b); F(1,33)=13.6, p<0.001 for the genotype, F(1,33)=1.33, p>0.05 for the treatment, F(1,33)=0.230, p>0.05 for the interaction in (c); F(1,33)=19.4, p<0.0001 for the genotype, F(1,33)=6.05, p<0.05 for the treatment, F(1,33)=0.253, p>0.05 for the interaction in (d); #p<0.05, ##p<0.01 vs same treatment WT mice; Bonferroni’s test.